The results showed that the 5 hmC model not only accurately distinguished patients with early-stage liver cancer from healthy controls, but also could distinguish patients with early-stage liver cancer from patients with chronic hepatitis B or cirrhosis, and its prediction performance was significantly better than that of AFP. The gene discussed is AFP; the disease is Cirrhosis.